In:
Ophthalmic Surgery, Lasers and Imaging Retina, SLACK, Inc., Vol. 29, No. 11 ( 1998-11), p. 909-915
Abstract:
* BACKGROUND AND OBJECTIVE: It is not rare for patients receiving anticoagulant therapy to undergo ocular surgery; however, there are no clear guidelines with reference to the operative management of the eye. This study examines the complications in patients receiving anticoagulant therapy who undergo ocular operations and suggests a management regimen for these patients. * PATIENTS AND METHODS: The authors retro spectively analyzed 52 patients receiving anticoagulant therapy who underwent ocular surgery between 1 993 and 1995. Data included sex, age, reason for anticoagulant therapy, operative procedure, complication rate, and length of time anticoagulant therapy was stopped or reduced prior to surgery. To show the base-line complication rate at their institution, data of patients not receiving anticoagulation therapy were added. * RESULTS: Ticlopidine hydrochloride, an antiplatelet drug, was administered to 24 patients. Warfarin sodium was administered to 8 patients, heparin was administered to 8 patients, and other anticoagulants were administered to 20 patients. There were no significant differences in complications between the groups that stopped or reduced anticoagulant therapy and those that did not, but speech disturbance due to thrombotic complication occurred in 1 of 10 patients in whom ticlopidine hydrochloride was stopped or reduced. Hemorrhagic complications occurred in 50% of those who continued ticlopidine hydrochloride, but in none of those who discontinued it (P = .019). There was a significant difference in hemorrhagic complications after cataract surgery between the phacoemulsification, aspiration, and intraocular lens implantation (PEA+ IOL) and the planned extracapsular cataract extraction and intraocular lens implantation (PECCE+IOL) groups that continued the drug (P= .0011). No patients showed visual acuity reduction due to hemorrhagic complications. * CONCLUSIONS: To avoid life-threatening systemic complications, one need not always stop anticoagulant therapy before performing only cataract surgery. Cataract surgery in patients receiving ticlopidine hydrochloride should be performed with PEA+IOL via a small sclerocorneal or a corneal incision. In cataract surgery for patients receiving anticoagulant therapy, hemorrhagic complications are more frequent than in patients not receiving anticoagulant therapy. [Ophthalmic Surg Lasers 1998;29:909-915.]
Type of Medium:
Online Resource
ISSN:
2325-8160
,
2325-8179
DOI:
10.3928/1542-8877-19981101-08
Language:
English
Publisher:
SLACK, Inc.
Publication Date:
1998
Permalink
